“parkinsons-disease” Archives

in
Entry Author Date Location
Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another 11/20/17 New York
Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study 11/15/17 New York
Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More 11/03/17 National
Bio Roundup: Graham-Cassidy, Axovant Fail, SpringWorks Launches & More 09/29/17 National
23andMe Raises $250M For Consumer Disease-Risk Tests, Drug R&D 09/12/17 San Francisco
All Eyes on Depression Trials as Sage Neuro Drug Flunks Epilepsy Test 09/12/17 Boston
Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More 09/08/17 National
Bio Roundup: CAR-T’s Huge Week, Merck’s ‘Pib Choice & More 09/01/17 National
FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble 08/29/17 New York
Bio Roundup: Drug Price Debates, NY Bio Blooms & CEOs Take Social Stand 08/25/17 National
Bio Roundup: $1B Deals, Data Bumps, Acorda’s Lumps, Generic OKs & More 08/11/17 National
E-Scape Unveils $63M for Alzheimer’s, Parkinson’s Drug Research 07/12/17 San Francisco
Acorda Touts Success in Parkinson’s Drug Study, Awaits Safety Data 02/09/17 New York
Allergan, Eying More Neurodegenerative Drugs, Gets Right to Buy LTI 01/09/17 Boston
Bio Roundup: Fast “Cures,” Trump In Time, CRISPR In Court & More 12/09/16 National
Voyager’s Gene Therapy for Parkinson’s Shows Promise in Small Study 12/07/16 Boston
Bio Roundup: CAR-T Ups & Downs, Lilly’s Failure, Myeloma & More 12/02/16 National
With $19M, Axial Becomes Latest Startup to Target Gut-Brain Connection 11/30/16 Boston
Acorda Leans on Parkinson’s Drugs After Post-Stroke Study Fails 11/21/16 New York
Promentis, Kiio, EmOpti, & More: This Week’s Wisconsin Watchlist 10/12/16 Wisconsin
With New Name and $47M, Proclara Begins First Big Alzheimer’s Test 09/07/16 Boston
Bio Roundup: RIP Roger Tsien, Novartis CAR-T Wheel, Zika News & More 09/02/16 National
Indiana’s SpeechVive Nabs $2M for Parkinson’s Speech Devices 05/18/16 Indiana
East Coast Biotech Roundup: Alkermes, Zafgen, Snowmaggedon & More 01/22/16 Boston
Acorda Doubles Down on Parkinson, Buys Biotie For $363M 01/19/16 New York
To Curb Brain Damage, Astrocyte Pharmaceuticals Energizes Cells 10/19/15 Texas
Voyager Charts an IPO Course Amid Choppy Biotech Waters 10/11/15 Boston
Acadia, Under New CEO, Seeks Approval for Parkinson’s Drug 09/03/15 San Diego
23andMe Adds On: More About The Gene-Test Maker’s Drug R&D Ambitions 03/12/15 San Francisco
23andMe Pharma? That’s the Plan, Says the Genetic Test Maker 03/12/15 San Francisco
Page 1 of 3 next page »